Navigation Links
U.S. Patent 7,299,083 Awarded to Signalife
Date:11/30/2007

LOS ANGELES, Nov. 30 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN) announced that The United States Patent and Trademark Office has awarded to the company patent #7,299,083 entitled "Electrode For, And Method Of, Indicating Signal Characteristics At Particular Positions In A Patient's Body". This patent, which covers 56 patent claims, is one of several patents filed by Signalife over the last five years.

Dr. Budimir S. Drakulic, Signalife's Chief Technology Officer, stated: "At the company's inception we carefully assessed the field of electrocardiography and electrocardiographic devices. Each aspect of electrocardiographic monitoring was scrutinized. Based on the knowledge gained during this assessment process, we developed a solution for ultimate electrocardiographic devices. Patent applications were filed for patents only upon the complete verification of the underlying scientific principles. I am very proud of our research and development team, which has developed a very significant patent portfolio. Under the leadership of Dr. Lowell Harmison, our new CEO, we are now making an important impact in the cardiac market".

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.

Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Signalife, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. Pressure BioSciences, Inc. Issued First Patent in Canada
4. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
5. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
6. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
7. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
8. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
9. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
10. Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent
11. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, ... after being treated for breast cancer benefitted from an injection of stem cells derived ... debilitating, frequent side effect of cancer treatment. , Lymphedema refers to the ...
Breaking Biology Technology:
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:6/1/2016)... -- Favorable Government Initiatives Coupled With Implementation ... to Boost Global Biometrics System Market Through 2021  ... " Global Biometrics Market By Type, By End ... - 2021", the global biometrics market is projected to ... growing security concerns across various end use sectors such ...
Breaking Biology News(10 mins):